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Clinical use of Levofloxacin 
in the long term treatment of drug
resistant tuberculosis
L. Richeldi, M. Covi, G. Ferrara, F. Franco, P. Vailati, E. Meschiari, 
L.M. Fabbri, G.Velluti
Multidrug-resistant tuberculosis (MDR TB) is
a form of TB that is resistant to the first-line drugs
[at least rifampin (RAMP) and isoniazid (INH)]
recommended for the treatment of the disease
(table 1). When compared to TB, MDR TB is as-
sociated with both higher incidence of treatment
failures and disease recurrence, as well as with
higher mortality [1]. Thus, in the case of MDR TB
second-line drugs must be introduced, although
they may present disadvantages in terms of effec-
tiveness, side effects and costs [2].
Standardized therapeutic guidelines for MDR
TB have yet to be developed. Thus, treatment reg-
imens are individualized on the basis of: i) the pa-
tient’s clinical history, ii) antibiogram (when avail-
able), and iii) the physician’s experience. World
Health Organization (WHO) guidelines recom-
mend regimens consisting of at least 3 drugs,
preferably 4 or 5, not previously administered to
the patient, of proven sensitivity, for at least 18
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ABSTRACT: Clinical use of Levofloxacin in the long term
treatment of drug resistant tuberculosis. L. Richeldi, 
M. Covi, G. Ferrara, F. Franco, P. Vailati, E. Meschiari,
L.M. Fabbri, G.Velluti.
Multidrug-resistant (MDR) tuberculosis (TB) is a
form of TB that is resistant to some of the first-line drugs
used for the treatment of the disease. It is associated both
with a higher incidence of treatment failures and of disease
recurrence, as well as with higher mortality than forms of
TB sensitive to first-line drugs. Levofloxacin (LFX) repre-
sents one of the few second-line drugs recently introduced
in the therapeutic regimens for MDR TB. We report our
experience concerning in vitro activity and clinical safety of
LFX in long term second-line regimens for MDR TB.
In vitro activity on Mycobacteria: The in vitro activity
of ciprofloxacin, ofloxacin and LFX was studied on 28
strains belonging to different species of Mycobacteria. In
Dubos medium, LFX inhibited the growth of both library
and MDR clinical Mycobacteria strains in a range of 0.25-
1 mcg/ml. In International Union Tuberculosis Medium
(IUTM) the minimum inhibitory concentrations (MIC)
were slightly higher, but LFX activity was not affected by
the higher complexity of the medium.
Clinical Experience: Four patients with MDR TB
were treated with a second-line regimen comprising oral
LFX 500 mg twice daily, for at least 9 months. Two isolates
obtained from the patients reported here showed multi re-
sistance to isoniazid and rifampin, one to rifampin and
streptomycin and one to isoniazid and ethambutol. During
therapy, no significant alteration of either liver function
tests, blood tests or any other described side effect of the
fluoroquinolone class was observed. The 3 patients with
pulmonary MDR TB showed radiologic and clinical im-
provement.
Conclusion: We confirm the higher in vitro activity of
LFX compared to older fluoroquinolones. Furthermore,
in a limited number of MDR TB patients, second-line reg-
imens comprising LFX 500 mg b.i.d. administered in a
range of 9-24 months were well tolerated and safe.
Monaldi Arch Chest Dis 2002; 57: 1, 39–43.
Table 1. – First and second-line drugs for the treatment
of multidrug-resistant tuberculosis (MDR TB)
First-line drugs Second-line drugs
Isoniazid Amikacin/Kanamycin
Rifampin Capreomycin
Ethambutol O-/Cipro-/Levo-/Moxi-floxacin
Pyrazinamide Ethionamide
Streptomycin Clofazimine
Cycloserine/Terizidone
Aminosalicilic acid
Rifabutin
Amoxycillin/Clavulanic acid
Modified from: [3].
months after sputum conversion. Treatment ad-
ministration should be directly observed (Directly
Observed Therapy, DOT) [3]. Many studies have
shown the in vitro and in vivo activity of fluoro-
quinolones against Mycobacterium tuberculosis
[4–10]. Thus, their use as second-line treatment of
MDR TB has been recommended by the WHO [2,
3, 11]. Levofloxacin (LFX) is the pure (-)-(S)-
enantiomer of the racemic drug substance
ofloxacin and it has recently become available for
therapy (1993 in USA, 1998 in Italy). The mecha-
nism of action relies on the DNA-DNA-gyrase
complex by inhibiting DNA gyrase (topoiso-
merase II) mainly in Gram-negative bacteria, and
topoisomerase IV mainly in Gram-positive bacte-
ria, but no studies on the LFX molecular target in
Mycobacteria have been published [12]. LFX is
the first long half-life (>7 hours) fluoroquinolone
available for clinical use at a once daily schedule,
moxifloxacin being only recently released in Italy
while gatifloxacin is expected in the next few
years. In terms of pharmacodynamics, the clinical
efficacy of LFX in community-acquired infections
has been shown to be predicted by the ratio of the
area under the curve (AUC) to the minimum in-
hibitory concentrations (MIC), or by the maximum
plasma concentration (Cmax)/MIC ratio [13].
Amongst these drugs, LFX has the largest document-
ed tolerability in terms of treated patients [14–16].
After the international clinical development
program, LFX has shown good tolerability. Unde-
sired side effects included those already reported
either for fluoroquinolones or other antibiotics (i.e.
nausea, diarrhea, headache) [16]. In particular,
there was not a statistically significant incidence of
either cardiovascular (prolonged Q-T, torsade de
pointe) or hepatic/pancreatic events. Furthermore,
post marketing surveillance has shown for LFX a
very good safety profile: in particular, undesired
events (pathologic manifestations that do not de-
pend directly on the cause-effect relationship with
the drug) are very rare (<0.01%) (table 2) [15].
The aim of this study was to retrospectively
evaluate the clinical use of LFX in long term ther-
apies in association with other first- and second-
line anti-TB drugs in patients with MDR TB or TB
caused by RAMP-resistant strains.
In vitro activity on M. Tuberculosis
Before introducing LFX into the treatment of
TB, some in vitro experiments on Mycobacteria
were carried out at our Institution. The in vitro ac-
tivity of ciprofloxacin, ofloxacin and LFX was
evaluated on: 2 strains from a human library and
18 clinical isolates of M. tuberculosis; 8 strains of
Mycobacterium avium complex (MAC); and 2 
Mycobacterium bovis strains. The activity of the 3
antimicrobial agents was assayed in Dubos broth
and in the agar medium, International Union Tu-
berculosis Medium (IUTM). Controls (i.e. tests
without drugs) were also introduced. Mycobacte-
ria inocula were set by turbidimetry to <100
Colony Forming Units (CFU). The strains that
showed a 5-10% growth with respect to the con-
trols were considered resistant to the specific con-
centration of fluoroquinolone tested.
In the broth medium, LFX inhibited the growth
of all the M. tuberculosis strains in a concentration
range of 0.25-1 mcg/ml. In IUTM, MIC values
were slightly higher. However, 2 strains of MDR
M. tuberculosis were inhibited by LFX concentra-
tions of 0.5 and 1 mcg/ml, respectively.
Ciprofloxacin and ofloxacin did not inhibit any
strain below the concentration of 1 mcg/ml: 10 M.
tuberculosis strains were inhibited in a range of 1-
5 mcg/ml, the remaining strains being resistant al-
so to concentrations above 5 mcg/ml. All MAC
and M. bovis isolates were resistant to the 3 study
drugs, up to a concentration of 10 mcg/ml.
Clinical experience
To evaluate tolerability and safety of LFX in
long term (more than 3 months) second-line regi-
mens, we retrospectively reviewed clinical, radio-
logic and laboratory data of 4 patients treated at
our Institution between December 1999 and Sep-
tember 2000 for MDR TB. A description of each
case follows.
Patient 1: 41-year-old Caucasian female, no
concomitant disease. In her past medical history
she reported having been treated in 1991 and 1995
with standard treatment for cavitary pulmonary
bacilliferous TB with severe fibrocavitary seque-
lae in both lung upper lobes. In both episodes the
patient voluntarily quitted treatment, at 3 and 5
months respectively. Following the occurrence of
persistent dry cough, high resolution computed to-
mography (HRCT) of the chest was performed,
which showed a “tree-in-bud” image (figure 1).
After fiberoptic bronchoscopy, the microscopic
examination of the bronchial exudate was negative
for acid fast bacilli (AFB), whereas the molecular
test (LCx® method, Abbott Diagnostics, US) re-
sulted positive. The patient was initially treated
with LFX (500 mg twice a day), INH (300 mg
once a day), pyrazinamide (PZA) (1200 mg once a
day), ethambutol (ETB) (1200 mg once a day) and
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Table 2. – Incidence rates of minor levofloxacin (LFX)
undesired events
Number of patients exposed to LFX: 2.000.000
Number of reported events: 193 (Incidence <0.01%)
Affected organ/apparatus N %
Aspecific 40 21
Skin 37 19
Central nervous system (CNS) 35 18.5
Muscles/Tendons 35 17.5
Digestive 21 11
Respiratory 15 8
Cardiovascular 10 5
Total 193 100
Modified from: [15].
rifabutin (RBT) (300 mg once a day). The suscep-
tibility test for M. tuberculosis showed ETB and
INH resistance. Thus, the therapy was modified as
follows: LFX (500 mg twice a day), PZA (1200
mg once a day), INH (300 mg once a day), RBT
(300 mg once a day) and clofazimine (CLF) (100
mg once a day). This regimen was then continued
for 12 months. At the end of the treatment period,
the patient had improved both clinically and radio-
logically.
Patient 2: 39-year-old Caucasian male, no
concomitant disease. In 1999, the patient was
treated with a standard 5-drug regimen for cavitary
pulmonary TB of both upper lobes with severe fi-
brocavitary sequelae. One year after completing
treatment, following the reappearance of asthenia,
fever and cough with purulent expectoration, the
patient was readmitted with the diagnosis of pul-
monary bacilliferous TB relapse. The following
regimen was introduced: LFX (500 mg twice a
day), ETB (1500 mg once a day), PZA (1500 mg
once a day), INH (300 mg once a day) and CLF
(100 mg once a day). Susceptibility test on M. tu-
berculosis isolate revealed RAMP and strepto-
mycin (STM) resistance. After 3 months of treat-
ment and sputum conversion, the patient was dis-
charged and continued the initial regimen for a fur-
ther 6 months. Thereafter, he continued the treat-
ment with INH, ETB and PZA for 6 months. The
clinical picture showed improvement but radiolog-
ical findings remained unchanged.
Patient 3: 77-year-old Caucasian female, af-
fected by herpetic neuritis of the right eye. At the
time of admission the patient was on full-dosage
RAMP-INH-ETB regimen for genitourinary TB.
Despite therapy, the general conditions and blood
chemistry tests worsened. The M. tuberculosis
strain obtained from a urinary specimen revealed
RAMP and INH resistance. Due to a variety of
drug intolerances, a 2-drug regimen with LFX
(500 mg twice a day) and terizidone (TZD) (250
mg three times a day) was adopted. Therapy led to
an improvement of the patient’s clinical condition
and to stabilization of the radiological and func-
tional findings. However, the urine specimens
were persistently positive for M. tuberculosis after
2 years of treatment.
Patient 4: 65-year-old Caucasian male, affect-
ed by chronic respiratory failure (treated with long
term oxygen therapy), type 2 diabetes, bilateral
arthrosis of the hip and chronic liver disease due to
alcohol. Five months before admission, the patient
had been treated with a standard 5-drug regimen
for pulmonary bacilliferous TB. The patient volun-
tarily stopped treatment after 2 months. He was ad-
mitted to our Clinic following the reoccurrence of
cough with purulent expectoration, low grade
fever and asthenia. Radiographic evaluation
showed a cavity in the apical segment of the left
lower lobe. Direct examination of sputum showed
AFB. The patient was initially treated with full-
dose RAMP, INH, ETB, PZA and ofloxacin. How-
ever, after the first month of treatment, the clinical
and radiological findings were still unchanged.
The drug susceptibility test confirmed the clinical
suspect of RAMP and INH resistance. Thus, a reg-
imen with LFX (500 mg twice a day), ETB (1500
mg once a day), INH (300 mg once a day), PZA
(1500 mg once a day), CLF (100 mg once a day)
was adopted, yielding to an improvement in the
clinical conditions. The radiologic findings slowly
improved, as documented by a series of chest
HRCT scans (figure 2). Cultural examinations for
M. tuberculosis converted to negative after 12
months, whereas all other microbiologic exams re-
mained persistently positive. Anti-TB therapy was
continued for a total of 12 months.
Safety and tolerability evaluation results
Laboratory test review did not reveal any sig-
nificant alteration in any of the patients. In partic-
ular, liver function tests [bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase, gamma glutamyl
transpeptidase (g -GT)] did not increase beyond 3
times normal values, even though other potentially
hepatotoxic drugs were included in the association
therapy. Hematopoiesis indexes did not show any
alteration. No side effect described for the LFX
pharmacological class was observed, including
gastrointestinal (diarrhea), cardiovascular (rhythm
alteration) and skeletal muscle (tendon breakage)
side effects. Patient 4 experienced two epilepsy-
like seizures which could not be explained other-
wise and did not require modification of therapy
since the electroencephalogram (EEG) and the
brain computed tomography (CT) scan performed
out after the episodes did not show any alteration.
The same patient repeatedly complained of gonal-
gia, which was probably due to a pre-existent
arthrosis of the knee and to hyperuricemia sec-
ondary to pyrazinamide therapy. Patient 2 com-
plained of headache during the first month of treat-
ment. However, he had previously shown an anx-
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Fig. 1. – High resolution computed tomography (HRCT) scan of 
patient 1 at the beginning of treatment with LFX, showing a “tree-
in-bud” appearance.
ious personality. All 3 patients affected by pul-
monary TB showed radiologic and clinical im-
provement of the lesions during treatment.
Discussion
MDR TB is a form of TB that is resistant to the
first-line drugs (at least RAMP and INH) used for
the treatment of the disease. When compared to
forms of TB that are sensitive to first-line drugs,
MDR TB is associated with a higher incidence
both of treatment failures and of disease recur-
rence, as well as with higher mortality [2]. The in-
creasing prevalence of MDR TB, especially in de-
veloping countries, highlights the need for new
treatment strategies including second-line drug
regimens in the DOT strategy (the so-called
“DOTS plus”) [17, 18]. Despite research efforts
regarding new therapeutic agents active against re-
sistant M. tuberculosis strains, fluoroquinolones
are the only new antimicrobial agents introduced
in the last 20 years in anti-TB regimens and evidence
of their clinical efficacy is increasing [19, 20].
We report here our experience on in vitro ac-
tivity and clinical use of LFX. LFX showed a 2-4
times higher in vitro activity against resistant and
MDR M. tuberculosis strains with respect to
ciprofloxacin and ofloxacin, both in broth and agar
media, in accordance with available published da-
ta [21]. No activity was shown against MAC
strains. However, it should be remembered that the
in vitro testing of Mycobacteria is far from being
standardized and that high intra- and extra-labora-
tory variability is to be expected. Thus, more ac-
curate and reproducible results will be available
when a general consensus on the Mycobacteria in
vitro assay is reached.
We retrospectively reviewed the LFX safety
and tolerability in 4 patients treated over a period
of 9-24 months with second-line regimens com-
prising LFX 500 mg twice a day. The reason for
the higher LFX daily dose was to address the phar-
macodynamic properties of the drug. The clinical
efficacy of LFX has been shown to be predicted by
the AUC/MIC or Cmax/MIC ratios [13]. Anecdot-
ic reports are available on the efficacy of LFX in
the treatment of TB, but no data on MDR TB LFX
therapy could be found. To raise the expected clin-
ical efficacy of LFX, we decided to increase the
daily AUC/MIC ratio, the drug’s Cmax being al-
ready elevated (5.7 mg/L in healthy subjects) [14]
and the toxic effect of fluoroquinolones being con-
centration dependent [16]. Furthermore, shorter
courses of LFX 500 mg b.i.d. in severe infections
have been published [22].
Laboratory tests failed to show any significant
alteration, especially in liver function tests (biliru-
bin, AST, ALT, alkaline phosphatase, g -GT) and
red blood cells and platelets counts. No adverse ef-
fect typical of the LFX pharmacological class was
observed. Patient 4 experienced two epilepsy-like
seizures which could not be explained otherwise
and did not require discontinuation of the drug. Pa-
tient 2 complained of headache during the first
month of treatment.
Overall, we confirm the higher in vitro activi-
ty of LFX compared to older fluoroquinolones.
Furthermore, in a limited number of MDR TB pa-
tients, second-line regimens comprising LFX 500
mg b.i.d. administered in a range of 9-24 months
were well tolerated and safe.
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